Pyrogallol: Target Organs and Levels of Evidence for TR-574
Toxicology and Carcinogenesis Studies of Pyrogallol (CASRN 87-66-1) in F344/N Rats and B6C3F1 Mice (Topical Application Studies)
Chemical (Study Title) CASRN | Peer Review Date | Route/Exposure Levels | Study Laboratory |
---|
Pyrogallol 87-66-1 | 02/08/2012 | Topical Application R&M: 0, 5, 20, OR 75 MG/KG; 50/SEX/SPECIES/DOSE | Battelle Columbus Laboratory |
Levels of Evidence
Male Rats: No Evidence
Type | Organ/Tissue (Lesion) |
---|
Non-Neoplastic Lesions | - Skin (site of application): hyperplasia; hyperkeratosis; inflammation; sebaceous gland, hyperplasia
|
Female Rats: No Evidence
Type | Organ/Tissue (Lesion) |
---|
Non-Neoplastic Lesions | - Skin (site of application): hyperplasia; hyperkeratosis; inflammation; sebaceous gland, hyperplasia
|
Male Mice: Equivocal Evidence
Type | Organ/Tissue (Lesion) |
---|
May Have Been Related | - Skin:
(site of application): squamous cell carcinoma 0/50, 0/50, 0/50, 2/50
|
Non-Neoplastic Lesions | - Skin (site of application): hyperplasia; hyperkeratosis; inflammation; fibrosis; pigmentation; sebaceous gland, hyperplasia; ulcer
- Skin: hyperplasia; hyperkeratosis; ulcer; inflammation; fibrosis
|
Female Mice: Some Evidence
Type | Organ/Tissue (Lesion) |
---|
Neoplastic Lesions | - Skin:
(site of application): squamous cell carcinoma 0/50, 0/50, 0/50, 4/50
|
Non-Neoplastic Lesions | - Skin (site of application): hyperplasia; hyperkeratosis; inflammation; fibrosis; pigmentation; sebaceous gland, hyperplasia; ulcer
- Skin: hyperplasia; hyperkeratosis; ulcer; inflammation; fibrosis; sebaceous gland, hyperplasia
- Mammary gland: hyperplasia
|